Tolerance induction via mixed chimerism in vascularized composite allotransplantation: Is it time for clinical application?

Current Opinion in Organ Transplantation

Volumn 20, Issue 6, 2015, Pages 602-607

  Cetrulo, Curtis L ^a   Drijkoningen, Tessa ^a   Sachs, David H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Mixed chimerism; Tolerance; Vascularized composite allograft

Indexed keywords

ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHIMERA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; KIDNEY GRAFT; MEMORY T LYMPHOCYTE; MIXED CHIMERISM; NONMYELOABLATIVE CONDITIONING; REVIEW; STEM CELL TRANSPLANTATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; ANIMAL; HISTOCOMPATIBILITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ANIMALS; HUMANS; IMMUNOLOGIC MEMORY; KIDNEY TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84947079451     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000248     Document Type: Review

References (38)

1. Bertrand AA, Sen S, Otake LR, Lee GK. Changing attitudes toward hand allotransplantation among North American hand surgeons. Ann Plast Surg 2014; 72:S56-S60.
2. Khalifian S, Brazio PS, Mohan R, et al. Facial transplantation: the first 9 years. Lancet 2014; 384:2153-2163.
3. Kawai T, Leventhal J, Madsen JC, et al. Tolerance: one transplant for life. Transplantation 2014; 98:117-121.
4. Leonard DA, Kurtz JM, Cetrulo CL Jr. Achieving immune tolerance in hand and face transplantation: a realistic prospect? Immunotherapy 2014; 6:499-502.
5. Sachs DH, Kawai T, Sykes M. Induction of tolerance through mixed chimer-ism. Cold Spring Harb Perspect Med 2014; 4: a015529.
6. Petruzzo P, Dubernard JM. The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl 2011; 247-253.
7. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity trans plantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013; 257:345-351.
8. Leto Barone AA, Shanmugarajah K, Leonard DA, Kurtz JM, Albritton A, et al. Effects of transient donor chimerism on rejection of MHC-mismatched vascularized composite allografts in swine. Vasc Compos Allotransplant 2015; 1: 1, 1-8, DOI: 10.1080/23723505.2015.1039692.
9. Brazio PS, Woodall J, Panda A, et al. Infused bone marrow fails to prevent vascularized composite allograft rejection in nonhuman primates. Am J Transplant 2015; 15:2011-2012.
10. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014; 14:1599-1611.
11. Leonard DA, Kurtz JM, Mallard C, et al. Vascularized composite allograft tolerance across MHC barriers in a large animal model. Am J Transplant 2014; 14:343-353.
12. Yamada Y, Benichou G, Cosimi AB, Kawai T. Tolerance induction after organ transplantation, "delayed tolerance" via the mixed chimerism approach: planting flowers in a battle field. Chimerism 2012; 3:24-28.
13. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120:4285-4291.
14. Huang Y, Bozulic LD, Miller T, et al. CD8a+ plasmacytoid precursor DCs induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood 2011; 117:2494-2505.
15. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:124ra28.
16. Strober S, Dhillon M, Schubert M, et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 1989; 321:28-33.
17. Strober S, Benike C, Krishnaswamy S, et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and antidonor reactivity. Transplantation 2000; 69:1549-1554.
18. Saper V, Chow D, Engleman ED, et al. Clinical and immunological studies of cadaveric renal transplant recipients given total-lymphoid irradiation and maintained on low-dose prednisone. Transplantation 1988; 45:540-546.
19. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosup-pressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73:1386-1391.
20. Millan MT, Shizuru SJ, Lowsky J, et al. Studies of tolerance and chimerism after combined blood stem cell and kidney transplantation in humans. Am J Transplant 2005; 5:544.
21. Mathes DW, Solari MG, Gazelle GS, et al. Stable mixed hematopoietic chimerism permits tolerance of vascularized composite allografts across a full major histocompatibility mismatch in swine. Transpl Int 2014; 27:1086-1096.
22. Vrecenak JD, Pearson EG, Santore MT, et al. Stable long-term mixed chimerism achieved in a canine model of allogeneic in utero hematopoietic cell transplantation. Blood 2014; 124:1987-1995.
23. Benichou G, Nadazdin O, Cosimi AB, Kawai T. Successful tolerance to fully MHC disparate renal allografts via donor hematopoietic mixed chimerism in nonhuman primates. Am J Transplant 2013; 13:2500.
24. Tonsho M, Lee S, Aoyama A, et al. Tolerance of lung allografts achieved in nonhuman primates via mixed hematopoietic chimerism. Am J Transplant 2015; 15:2231-2239.
25. Yamada Y, Boskovic S, Aoyama A, et al. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant 2012; 12:330-340.
26. Nadazdin O, Boskovic S, Murakami T, et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med 2011; 3:86ra51.
27. Lee S, Yamada Y, Tonsho M, et al. Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells. Am J Transplant 2013; 13:3223-3229; Oct 24.
28. Lee WP, Rubin JP, Cober S, et al. Use of swine model in transplantation of vascularized skeletal tissue allografts. Transplant Proc 1998; 30:2743-2745.
29. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003; 75:25-31.
30. Horner BM, Randolph MA, Duran-Struuck R, et al. Induction oftolerance to an allogeneic skin flap transplant in a preclinical large animal model. Transplant Proc 2009; 41:539-541.
31. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004; 77:514-521.
32. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4:117ra7.
33. Jiang X, Clark RA, Liu L, et al. Skin infection generates nonmigratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012; 483:227-231.
34. Di MP, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity 2011; 35:857-869.
35. Tay SS, Roediger B, Tong PL, et al. The skin-resident immune network. Curr Dermatol Rep 2014; 3:13-22.
36. Seneschal J, Clark RA, Gehad A, et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells. Immunity 2012; 36:873-884.
37. Bennett CL, Fallah-Arani F, Conlan T, et al. Langerhans cells regulate cutaneous injury by licensing CD8 effector cells recruited to the skin. Blood 2011; 117:7063-7069.
38. Kaplan DH. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol 2010; 31:446-451.